利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.015 秒)

    Controlled Release Formulations of Lorazepam
    2.
    发明申请
    Controlled Release Formulations of Lorazepam 审中-公开
    洛拉西泮控释制剂

    公开(公告)号：US20150190345A1

    公开(公告)日：2015-07-09

    申请号：US14150493

    申请日：2014-01-08

    申请人： Douglas A. Saltel ,  Michael Vachon

    发明人： Douglas A. Saltel ,  Michael Vachon

    IPC分类号： A61K9/20 ,  A61K31/5513

    CPC分类号： A61K9/2031 ,  A61K9/2009 ,  A61K9/2018 ,  A61K31/5513

    摘要： Controlled release of lorazepam can provide enhanced dosing options including once daily dosing that provides 24 hour therapeutic effect under steady state conditions. The pharmaceutical composition can provide substantially zero order release and 90% release within 7 to 12 hours in a pharmaceutical dissolution test. The release can be achieved using polyethylene oxide as a matrix polymer.

    摘要翻译： 控制释放的劳拉西泮可以提供增强剂量选择，包括每日一次给药，在稳态条件下提供24小时治疗效果。 药物组合物可以在药物溶出度测试中在7至12小时内提供基本上零级释放和90％释放。 可以使用聚环氧乙烷作为基质聚合物来实现释放。

    Sustained release formulations of lorazepam
    3.
    发明授权
    Sustained release formulations of lorazepam 有权
    持续释放的劳拉西泮制剂

    公开(公告)号：US08999393B1

    公开(公告)日：2015-04-07

    申请号：US14150375

    申请日：2014-01-08

    申请人： Douglas A. Saltel ,  Michael Vachon

    发明人： Douglas A. Saltel ,  Michael Vachon

    IPC分类号： A61K9/14 ,  A61K9/50

    CPC分类号： A61K9/5026 ,  A61K9/1652 ,  A61K9/4891 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/5513 ,  A61K47/36 ,  A61K47/38

    摘要： A pharmaceutical composition for delivering lorazepam in a prolonged fashion is achieved with prolonged release lorazepam pharmaceutical beads. The composition typically contains sustained release lorazepam beads and delayed sustained release lorazepam beads. The composition can provide once daily dosing that maintains 24 hour therapeutic effect under steady state conditions.

    摘要翻译： 用延长释放的劳拉西泮药物珠粒实现长时间递送劳拉西泮的药物组合物。 组合物通常含有持续释放的劳拉西泮珠和延迟的持续释放的劳拉西泮珠。 该组合物可以每天一次给药，在稳态条件下维持24小时的治疗效果。

    Analgesic compositions comprising anti-epileptic compounds and methods of using same
    4.
    发明授权
    Analgesic compositions comprising anti-epileptic compounds and methods of using same 失效
    包含抗癫痫化合物的止痛组合物及其使用方法

    公开(公告)号：US06942876B2

    公开(公告)日：2005-09-13

    申请号：US10075929

    申请日：2002-02-13

    申请人： Leslie Magnus-Miller ,  Douglas A. Saltel

    发明人： Leslie Magnus-Miller ,  Douglas A. Saltel

    IPC分类号： A61K45/00 ,  A61K31/195 ,  A61K31/197 ,  A61K31/22 ,  A61K31/415 ,  A61K31/47 ,  A61P29/02 ,  A61K9/14 ,  A61K9/20 ,  A61K9/48

    CPC分类号： A61K31/195 ,  A61K31/415 ,  A61K31/47 ,  A61K31/19 ,  A61K2300/00

    摘要： The present invention is directed to novel combinations of anti-epileptic compounds that demonstrate pain alleviating properties, with compounds selected from the group consisting of analgesics, NMDA receptor antagonists, and NSAIDs and pharmaceutical compositions comprising same. It has been discovered that the administration of anti-epileptic compounds that demonstrate pain alleviating properties in these novel combinations results in an improved reduction in the frequency and severity of pain. It is also believed that the incidence of unwanted side effects can be reduced by these novel combinations in comparison to using higher doses of a single agent treatment to achieve a similar therapeutic effect. The present invention is also directed to methods of using effective amounts of the novel pharmaceutical compositions to treat pain in mammals.

    摘要翻译： 本发明涉及具有减轻疼痛性质的抗癫痫化合物与选自镇痛药，NMDA受体拮抗剂和NSAID的化合物以及包含其的药物组合物的新型组合。 已经发现，在这些新型组合中表现出疼痛缓解性质的抗癫痫化合物的施用导致疼痛的频率和严重性的改善降低。 还认为与使用更高剂量的单一药物治疗以达到相似的治疗效果相比，这些新颖的组合可以减少不想要的副作用的发生率。 本发明还涉及使用有效量的新型药物组合物来治疗哺乳动物疼痛的方法。